A Phase 2 interventional study of IGIV-C and Placebo in Myasthenia Gravis, Generalized, sponsored by Grifols Therapeutics LLC. Completed at 40 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 51st largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2015, is one of 26 in phase 2, and was the 23rd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 3 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score from Baseline (Week 0) to Week 24 as compared to placebo.
The safety objective of this study is to evaluate the safety and tolerability of IGIV-C loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through Week 21 in subjects with MG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving standard of care MG treatment at a stable dose consisting of any one of the following for the time intervals delineated below (time intervals apply to medications and maintenance of stable dose level):
Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening AND/OR only one of the following:
Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening AND/OR prednisone (up to 60 mg/day or equivalent) for at least one month prior to Screening and only one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified. An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8).
Drug: IGIV-C
Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
Drug: Placebo
IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score.
To measure improvement in MG symptoms by the mean change in QMG total score from Baseline (Week 0) to Week 24 as compared to placebo. Evaluators score 13 individual items (range from 0=best to 3=worst) and the individual scores are added together for the total score (range 0-39). An average 3-point improvement in QMG score indicates clinically meaningful improvement.
Time frame: Baseline (Week 0) to Week 24
| Milestone | IGIV-C | Placebo |
|---|---|---|
| Started | 30 | 32 |
| Completed | 28 | 24 |
| Not completed | 2 | 8 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 6 |
To measure improvement in MG symptoms by the mean change in QMG total score from Baseline (Week 0) to Week 24 as compared to placebo. Evaluators score 13 individual items (range from 0=best to 3=worst) and the individual scores are added together for the total score (range 0-39). An average 3-point improvement in QMG score indicates clinically meaningful improvement.
| units on a scale | IGIV-C | Placebo |
|---|---|---|
| Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score. | -4.6 ± 5.11 | -2.7 ± 6.23 |
Collected over Adverse event data were collected from screening through Week 24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV-C | 1/30 (3.3%) | 5/30 (16.7%) | 22/30 (73.3%) |
| Placebo | 0/32 (0%) | 4/32 (12.5%) | 21/32 (65.6%) |
| Event | IGIV-C | Placebo |
|---|---|---|
| Myasthenia gravisNervous system disorders | 3/30 | 1/32 |
| Atrial fibrillationCardiac disorders | 1/30 | 0/32 |
| Cardiopulmonary failureCardiac disorders | 1/30 | 0/32 |
| Haemorrhoids thrombosedGastrointestinal disorders | 1/30 | 0/32 |
| PneumoniaInfections and infestations | 1/30 | 0/32 |
| Septic shockInfections and infestations | 1/30 | 0/32 |
| Panic attackPsychiatric disorders | 1/30 | 0/32 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/30 | 1/32 |
| Wrist fractureInjury, poisoning and procedural complications | 0/30 | 1/32 |
| Ischaemic strokeNervous system disorders | 0/30 | 1/32 |
| Event | IGIV-C | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 9/30 | 4/32 |
| NasopharyngitisInfections and infestations | 3/30 | 4/32 |
| DiarrhoeaGastrointestinal disorders | 3/30 | 2/32 |
| NauseaGastrointestinal disorders | 3/30 | 1/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/30 | 0/32 |
| HypertensionVascular disorders | 3/30 | 2/32 |
| Upper respiratory tract infectionInfections and infestations | 0/30 | 3/32 |
| ChillsGeneral disorders | 2/30 | 0/32 |
| FatigueGeneral disorders | 2/30 | 0/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/30 | 0/32 |
| Age, Continuous(years) | IGIV-C | Placebo | Total |
|---|---|---|---|
| Mean | 54.6 ± 17.06 | 48.0 ± 13.66 | 51.2 ± 15.63 |
| Age, Customized(Participants) | IGIV-C | Placebo | Total |
|---|---|---|---|
| <65 years | 20 | 29 | 49 |
| >=65 | 10 | 3 | 13 |
| Sex: Female, Male(Participants) | IGIV-C | Placebo | Total |
|---|---|---|---|
| Female | 14 | 19 | 33 |
| Male | 16 | 13 | 29 |
| Ethnicity (NIH/OMB)(Participants) | IGIV-C | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 28 | 29 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | IGIV-C | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 1 | 0 | 1 |
| White | 29 | 30 | 59 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | IGIV-C | Placebo | Total |
|---|---|---|---|
| North America | 11 | 12 | 23 |
| Europe | 19 | 20 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Jan 2018, 29 months.
Results were first posted in Mar 2019, 1 year 2 months after primary completion.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous